Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ADCY5 | O95622 | 5/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.32 |
| ▸ | MARS1 | P56192 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bch-1393 SCHEMBL14203135 | 1.00 | CYP1A2 (0.41) | CYP1A2CYP2D6MAPK1ADCY5ITGB3 | |
| Bch-1393 SCHEMBL8466563 | 1.00 | CYP1A2 (0.41) | CYP1A2CYP2D6MAPK1ADCY5ITGB3 | |
| SCHEMBL8467088 | 0.99 | CYP1A2 (0.42) | CYP1A2CYP2D6MAPK1ADCY5ITGB3 | |
| SCHEMBL8464129 | 0.99 | CYP1A2 (0.42) | CYP1A2CYP2D6MAPK1ADCY5ITGB3 | |
| SCHEMBL8467074 | 0.89 | P2RY1 (0.43) | ADCY5MARS1 | |
| SCHEMBL8464285 | 0.89 | P2RY1 (0.43) | ADCY5MARS1 | |
| SCHEMBL8465859 | 0.89 | ADCY5 (0.47) | ADCY5 | |
| SCHEMBL8466911 | 0.89 | ADCY5 (0.37) | ADCY5ITGB3ITGA2BMARS1 | |
| SCHEMBL8466600 | 0.89 | ADCY5 (0.47) | ADCY5 | |
| SCHEMBL8464552 | 0.89 | CYP1A2 (0.46) | CYP1A2CYP2D6MAPK1ADCY5ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5994361-A | ANTITUMOR, ANTICANCER AGENT | BIOCHEM PHARMA (CA) | 1999-11-30 | — | — | US | claimed |
| US-20080090848-A1 | Substituted Purinyl Derivatives With Immunomodulator And Chemoprotective Activity And Use Alone Or With Medium-Chain Length Fatty Acids Or Glycerides | PROMETIC BIOSCIENCES INC. (CA) | 2008-04-17 | — | — | US | disclosed |
| EP-1784190-A1 | SUBSTITUTED PURINYL DERIVATIVES WITH IMMUNOMODULATOR AND CHEMOPROTECTIVE ACTIVITY AND USE ALONE OR WITH MEDIUM-CHAIN LENGTH FATTY ACIDS OR GLYCERIDES | ProMetic BioSciences Inc. (CA) | 2007-05-16 | — | — | EP | disclosed |
| WO-2006024174-A1 | SUBSTITUTED PURINYL DERIVATIVES WITH IMMUNOMODULATOR AND CHEMOPROTECTIVE ACTIVITY AND USE ALONE OR WITH MEDIUM-CHAIN LENGTH FATTY ACIDS OR GLYCERIDES | PROMETIC BIOSCIENCES INC. (CA) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090848-A1 | Substituted Purinyl Derivatives With Immunomodulator And Chemoprotective Activity And Use Alone Or With Medium-Chain Length Fatty Acids Or Glycerides | PNLIP, THPO, MYD88 | CYP1A2 4281/4885CYP2D6 3667/4885MAPK1 3171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.